Verve Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 255
- Market Cap
- $467.1M
- Website
- http://www.vervetx.com
- Introduction
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.
11 Clinical Trials That Have Researchers Excited in 2024
2024 highlights 11 pivotal clinical trials across diseases like cancer, malaria, and HIV, and tech advancements in AI and stem cell therapy, showing promising results. Key studies include a breast cancer treatment with a 73.3% response rate, a malaria vaccine with 78% efficacy, and AI for early lung cancer detection, aiming to significantly impact future medicine.
CRISPR Clinical Trials: A 2024 Update
CRISPR-based therapies have achieved a milestone with the approval of Casgevy for sickle cell disease and beta thalassemia. Despite financial pressures and clinical trial challenges, CRISPR's potential in treating various diseases, including cancers and genetic disorders, is expanding. Innovations in delivery methods and regulatory approaches are key to future advancements.
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
Verve Therapeutics announced FDA clearance of its IND application for VERVE-101, a gene-editing treatment targeting PCSK9 to lower LDL-C in HeFH patients. The heart-1 trial, evaluating VERVE-101's safety and efficacy, progresses with interim data to be presented at AHA's 2023 Scientific Sessions.
© Copyright 2025. All Rights Reserved by MedPath